Moreover, the nature and intensity of chemokines response can reflect the location and severity of hepatic damage, suggesting that, unlike other chemokines, CCL20 may play an important role in NASH, implying that it could be an attractive candidate for NASH therapeutic targeting. Here, CCL20 is linked to metabolic dysfunction-associated steatohepatitis.